argenex (NASDAQ:ARGX) Given New $1,185.00 Price Target at Guggenheim

argenex (NASDAQ:ARGX) had its target price lifted by Guggenheim from $1,135.00 to $1,185.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

ARGX has been the topic of a number of other research reports. Oppenheimer reduced their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. HC Wainwright reiterated a “buy” rating and issued a $940.00 price objective on shares of argenex in a research note on Thursday, June 25th. Wedbush restated an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a report on Thursday, June 11th. Glj Research raised argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Finally, Citizens Jmp decreased their price objective on argenex from $944.00 to $932.00 and set a “market outperform” rating for the company in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,050.50.

argenex Trading Down 0.7%

ARGX opened at $918.22 on Friday. argenex has a 1-year low of $587.37 and a 1-year high of $953.58. The stock has a market cap of $57.44 billion, a PE ratio of 35.26, a price-to-earnings-growth ratio of 1.14 and a beta of 0.45. The stock’s fifty day simple moving average is $868.28 and its 200 day simple moving average is $815.12.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.86 by $1.46. argenex had a net margin of 32.19% and a return on equity of 70.27%. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. Equities analysts forecast that argenex will post 26.27 earnings per share for the current year.

Hedge Funds Weigh In On argenex

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sound Income Strategies LLC purchased a new position in argenex in the fourth quarter worth about $28,000. Whipplewood Advisors LLC bought a new stake in argenex during the first quarter valued at approximately $28,000. Eastern Bank purchased a new stake in argenex during the second quarter valued at approximately $32,000. Sunbelt Securities Inc. bought a new position in argenex in the third quarter worth approximately $36,000. Finally, Axiom Investment Management LLC purchased a new position in shares of argenex during the 1st quarter worth $50,000. Institutional investors own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.